IntelGenx Submits Response to CRL from FDA for RIZAPORT® VersaFilm®
globenewswire.com
news
2022-10-18 00:00:00

SAINT LAURENT, Quebec, Oct. 18, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical films, today announced that it has responded to the Complete Response Letter ('CRL') for its 505(b)(2) New Drug Application (NDA) for RIZAPORT® VersaFilm® received from the U.S. Food and Drug Administration ('FDA') in March 2020. 'We have been encouraged by our interactions with the FDA and are pleased to submit our response to the CRL,' commented Dr.
